Management of extranodal natural killer/T-cell lymphoma, nasal type

Ranjit Kumar Chaudhary, Vijaya R Bhatt, Julie Marie Vose

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Abstract Extranodal natural killer/T-cell lymphoma, nasal type (NKTL) is an uncommon aggressive subtype of non-Hodgkin lymphoma, which is significantly more common in East Asia and Latin America. Three-quarters of patients present with stage I/II disease, and half of patients have a low-risk International Prognostic Index score. Although additional factors including natural killer/T-cell lymphoma prognostic index and peripheral blood Epstein-Barr virus load influence the outcomes, the modality of treatment largely differs according to stage (based on nonrandomized studies). In early-stage disease, a combination of chemotherapy and involved-field radiotherapy (IFRT) appears to improve outcome compared with chemotherapy alone. Radiotherapy dose > 50 Gy, concurrent or sequential chemoradiation, and early use of IFRT results in better outcomes than doses < 50 Gy and delay in initiation of IFRT. In late-stage NKTL, chemotherapy alone is the mainstay of treatment. Compared with the CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) regimen, newer regimens containing L-asparaginase and gemcitabine result in better outcomes; however, toxicity might be an issue. Stem cell transplant has been used as salvage and consolidation therapy with some benefit, particularly in patients with advanced-stage disease in remission at the time of transplant; however, further confirmatory studies are needed. In the past decade, we have seen a significant growth in our understanding of the disease process and an increase in our armamentarium of effective therapeutics; however, further development of novel therapies and optimal selection of available therapy options via randomized trials are necessary to improve the outcomes of this aggressive lymphoma.

Original languageEnglish (US)
Article number536
Pages (from-to)245-252
Number of pages8
JournalClinical Lymphoma, Myeloma and Leukemia
Volume15
Issue number5
DOIs
StatePublished - May 1 2015

Fingerprint

Natural Killer T-Cells
T-Cell Lymphoma
Nose
Radiotherapy
gemcitabine
Transplants
Asparaginase
Drug Therapy
Salvage Therapy
Far East
Latin America
Vincristine
Therapeutics
Prednisone
Combination Drug Therapy
Human Herpesvirus 4
Non-Hodgkin's Lymphoma
Doxorubicin
Cyclophosphamide
Lymphoma

Keywords

  • Epstein-Barr virus
  • Gemcitabine
  • Involved-field radiotherapy
  • L-asparaginase
  • Natural killer/T-cell lymphoma prognostic index

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Management of extranodal natural killer/T-cell lymphoma, nasal type. / Chaudhary, Ranjit Kumar; Bhatt, Vijaya R; Vose, Julie Marie.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 15, No. 5, 536, 01.05.2015, p. 245-252.

Research output: Contribution to journalArticle

@article{7fa749ce89464591ae137e069bab3d72,
title = "Management of extranodal natural killer/T-cell lymphoma, nasal type",
abstract = "Abstract Extranodal natural killer/T-cell lymphoma, nasal type (NKTL) is an uncommon aggressive subtype of non-Hodgkin lymphoma, which is significantly more common in East Asia and Latin America. Three-quarters of patients present with stage I/II disease, and half of patients have a low-risk International Prognostic Index score. Although additional factors including natural killer/T-cell lymphoma prognostic index and peripheral blood Epstein-Barr virus load influence the outcomes, the modality of treatment largely differs according to stage (based on nonrandomized studies). In early-stage disease, a combination of chemotherapy and involved-field radiotherapy (IFRT) appears to improve outcome compared with chemotherapy alone. Radiotherapy dose > 50 Gy, concurrent or sequential chemoradiation, and early use of IFRT results in better outcomes than doses < 50 Gy and delay in initiation of IFRT. In late-stage NKTL, chemotherapy alone is the mainstay of treatment. Compared with the CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) regimen, newer regimens containing L-asparaginase and gemcitabine result in better outcomes; however, toxicity might be an issue. Stem cell transplant has been used as salvage and consolidation therapy with some benefit, particularly in patients with advanced-stage disease in remission at the time of transplant; however, further confirmatory studies are needed. In the past decade, we have seen a significant growth in our understanding of the disease process and an increase in our armamentarium of effective therapeutics; however, further development of novel therapies and optimal selection of available therapy options via randomized trials are necessary to improve the outcomes of this aggressive lymphoma.",
keywords = "Epstein-Barr virus, Gemcitabine, Involved-field radiotherapy, L-asparaginase, Natural killer/T-cell lymphoma prognostic index",
author = "Chaudhary, {Ranjit Kumar} and Bhatt, {Vijaya R} and Vose, {Julie Marie}",
year = "2015",
month = "5",
day = "1",
doi = "10.1016/j.clml.2014.12.014",
language = "English (US)",
volume = "15",
pages = "245--252",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",
number = "5",

}

TY - JOUR

T1 - Management of extranodal natural killer/T-cell lymphoma, nasal type

AU - Chaudhary, Ranjit Kumar

AU - Bhatt, Vijaya R

AU - Vose, Julie Marie

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Abstract Extranodal natural killer/T-cell lymphoma, nasal type (NKTL) is an uncommon aggressive subtype of non-Hodgkin lymphoma, which is significantly more common in East Asia and Latin America. Three-quarters of patients present with stage I/II disease, and half of patients have a low-risk International Prognostic Index score. Although additional factors including natural killer/T-cell lymphoma prognostic index and peripheral blood Epstein-Barr virus load influence the outcomes, the modality of treatment largely differs according to stage (based on nonrandomized studies). In early-stage disease, a combination of chemotherapy and involved-field radiotherapy (IFRT) appears to improve outcome compared with chemotherapy alone. Radiotherapy dose > 50 Gy, concurrent or sequential chemoradiation, and early use of IFRT results in better outcomes than doses < 50 Gy and delay in initiation of IFRT. In late-stage NKTL, chemotherapy alone is the mainstay of treatment. Compared with the CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) regimen, newer regimens containing L-asparaginase and gemcitabine result in better outcomes; however, toxicity might be an issue. Stem cell transplant has been used as salvage and consolidation therapy with some benefit, particularly in patients with advanced-stage disease in remission at the time of transplant; however, further confirmatory studies are needed. In the past decade, we have seen a significant growth in our understanding of the disease process and an increase in our armamentarium of effective therapeutics; however, further development of novel therapies and optimal selection of available therapy options via randomized trials are necessary to improve the outcomes of this aggressive lymphoma.

AB - Abstract Extranodal natural killer/T-cell lymphoma, nasal type (NKTL) is an uncommon aggressive subtype of non-Hodgkin lymphoma, which is significantly more common in East Asia and Latin America. Three-quarters of patients present with stage I/II disease, and half of patients have a low-risk International Prognostic Index score. Although additional factors including natural killer/T-cell lymphoma prognostic index and peripheral blood Epstein-Barr virus load influence the outcomes, the modality of treatment largely differs according to stage (based on nonrandomized studies). In early-stage disease, a combination of chemotherapy and involved-field radiotherapy (IFRT) appears to improve outcome compared with chemotherapy alone. Radiotherapy dose > 50 Gy, concurrent or sequential chemoradiation, and early use of IFRT results in better outcomes than doses < 50 Gy and delay in initiation of IFRT. In late-stage NKTL, chemotherapy alone is the mainstay of treatment. Compared with the CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) regimen, newer regimens containing L-asparaginase and gemcitabine result in better outcomes; however, toxicity might be an issue. Stem cell transplant has been used as salvage and consolidation therapy with some benefit, particularly in patients with advanced-stage disease in remission at the time of transplant; however, further confirmatory studies are needed. In the past decade, we have seen a significant growth in our understanding of the disease process and an increase in our armamentarium of effective therapeutics; however, further development of novel therapies and optimal selection of available therapy options via randomized trials are necessary to improve the outcomes of this aggressive lymphoma.

KW - Epstein-Barr virus

KW - Gemcitabine

KW - Involved-field radiotherapy

KW - L-asparaginase

KW - Natural killer/T-cell lymphoma prognostic index

UR - http://www.scopus.com/inward/record.url?scp=84928306209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928306209&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2014.12.014

DO - 10.1016/j.clml.2014.12.014

M3 - Article

VL - 15

SP - 245

EP - 252

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

IS - 5

M1 - 536

ER -